Jan Albert

List of Publications by Year
in descending order

97 papers	6,317 citations	101384 36 h-index	82410 72 g-index
115 all docs	115 docs citations	115 times ranked	11873 citing authors

#	Article	IF	Citations
1	A highly virulent variant of HIV-1 circulating in the Netherlands. Science, 2022, 375, 540-545.	6.0	39
2	Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load. Virus Evolution, 2022, 8, veac022.	2.2	1
3	Probabilistic classification of antiâ€šSARSâ€šCoVâ€‚2 antibody responses improves seroprevalence estimates. Clinical and Translational Immunology, 2022, 11, e1379.	1.7	4
4	Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infectious Diseases, The, 2022, 22, 813-820.	4.6	64
5	Evolution, geographic spreading, and demographic distribution of Enterovirus D68. PLoS Pathogens, 2022, 18, e1010515.	2.1	19
6	Contagiousness in treated HIV-1 infection. Infectious Diseases, 2021, 53, 1-8.	1.4	8
7	High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden. Aids, 2021, 35, 227-234.	1.0	3
8	Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020. Journal of Clinical Virology, 2021, 136, 104754.	1.6	25
9	Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. Journal of Clinical Investigation, 2021, 131, .	3.9	88
10	Seropositivity in blood donors and pregnant women during the first year of SARSâ€šCoVâ€‚2 transmission in Stockholm, Sweden. Journal of Internal Medicine, 2021, 290, 666-676.	2.7	34
11	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. JCI Insight, 2021, 6, .	2.3	27
12	Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021. Eurosurveillance, 2021, 26, .	3.9	36
13	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 2020, 183, 158-168.e14.	13.5	1,561
14	Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention. PLoS Computational Biology, 2020, 16, e1008122.	1.5	7
15	Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR. Nature Communications, 2020, 11, 4812.	5.8	357
16	Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12522-12523.	3.3	68
17	Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child. Infectious Diseases, 2020, 52, 419-422.	1.4	69
18	Antiretroviral treatment for HIV infection: Swedish recommendations 2019. Infectious Diseases, 2020, 52, 295-329.	1.4	13

#	Article	IF	Citations
19	Four SARS-CoV-2 Genome Sequences from Late April in Stockholm, Sweden, Reveal a Rare Mutation in the Spike Protein. Microbiology Resource Announcements, 2020, 9, .	0.3	9
20	Potential impact of seasonal forcing on a SARS-CoV-2 pandemic. Swiss Medical Weekly, 2020, 150, w20224.	0.8	223
21	Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention. , 2020, 16, e1008122.		0
22	Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention. , 2020, 16, e1008122.		0
23	Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention. , 2020, 16, e1008122.		0
24	Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention. , 2020, 16, e1008122.		0
25	Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention. , 2020, 16, e1008122.		0
26	Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention. , 2020, 16, e1008122.		0
27	Homogeneous Differential Magnetic Assay. ACS Sensors, 2019, 4, 2381-2388.	4.0	13
28	A5â€ƒNear full-length HIV-1 genome sequencing in newly diagnosed individuals in Sweden. Virus Evolution, 2019, 5, .	2.2	0
29	A Single-Stranded Oligonucleotide Inhibits Toll-Like Receptor 3 Activation and Reduces Influenza A (H1N1) Infection. Frontiers in Immunology, 2019, 10, 2161.	2.2	18
30	Characterization of Binding of Magnetic Nanoparticles to Rolling Circle Amplification Products by Turn-On Magnetic Assay. Biosensors, 2019, 9, 109.	2.3	2
31	Getting more from heterogeneous HIV-1 surveillance data in a high immigration country: estimation of incidence and undiagnosed population size using multiple biomarkers. International Journal of Epidemiology, 2019, 48, 1795-1803.	0.9	13
32	Intra- and interpatient evolution of enterovirus D68 analyzed by whole-genome deep sequencing. Virus Evolution, 2019, 5, vez007.	2.2	20
33	Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. Eurosurveillance, 2019, 24, .	3.9	4
34	Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. Aids, 2018, 32, 877-884.	1.0	9
35	Prophylaxis and treatment of HIV-1 infection in pregnancy â€“ Swedish Recommendations 2017. Infectious Diseases, 2018, 50, 495-506.	1.4	14
36	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. Virus Evolution, 2018, 4, vey007.	2.2	64

#	Article	IF	Citations
37	Padlock Probe Assay for Detection and Subtyping of Seasonal Influenza. Clinical Chemistry, 2018, 64, 1704-1712.	1.5	14
38	Expert consensus statement on the science of <scp>HIV</scp> in the context of criminal law. Journal of the International AIDS Society, 2018, 21, e25161.	1.2	59
39	Error rates, PCR recombination, and sampling depth in HIV-1 whole genome deep sequencing. Virus Research, 2017, 239, 106-114.	1.1	42
40	Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infectious Diseases, 2017, 49, 1-34.	1.4	24
41	Inference of Transmission Network Structure from HIV Phylogenetic Trees. PLoS Computational Biology, 2017, 13, e1005316.	1.5	26
42	In vivo mutation rates and the landscape of fitness costs of HIV-1. Virus Evolution, 2017, 3, vex003.	2.2	85
43	A35â€ƒViral evolution and innate immune responses during acute HIV-1 infection and their association with disease pathogenesis. Virus Evolution, 2017, 3, .	2.2	0
44	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biology, 2017, 15, e2001855.	2.6	38
45	Estimating time of HIV-1 infection from next-generation sequence diversity. PLoS Computational Biology, 2017, 13, e1005775.	1.5	45
46	Impaired B cells survival upon production of inflammatory cytokines by HIV-1 exposed follicular dendritic cells. Retrovirology, 2016, 13, 61.	0.9	23
47	The global spread of HIV-1 subtype B epidemic. Infection, Genetics and Evolution, 2016, 46, 169-179.	1.0	60
48	HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. Virus Evolution, 2016, 2, vew010.	2.2	68
49	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Infectious Diseases, 2016, 48, 93-98.	1.4	7
50	Molecular epidemiology and the evolution of human coxsackievirus A6. Journal of General Virology, 2016, 97, 3225-3231.	1.3	37
51	Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study. PLoS ONE, 2016, 11, e0157398.	1.1	28
52	How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Expertsâ€™ Opinion and Its Influence on the Projected Public Health Impact. PLoS ONE, 2016, 11, e0158620.	1.1	19
53	Outbreak of enterovirus D68 of the new B3 lineage in Stockholm, Sweden, August to September 2016. Eurosurveillance, 2016, 21, .	3.9	73
54	Establishment and stability of the latent HIV-1 DNA reservoir. ELife, 2016, 5, .	2.8	119

#	Article	IF	Citations
55	Challenges with Using Primer IDs to Improve Accuracy of Next Generation Sequencing. PLoS ONE, 2015, 10, e0119123.	1.1	27
56	Coexistence of two clades of enterovirus D68 in pediatric Swedish patients in the summer and fall of 2014. Infectious Diseases, 2015, 47, 734-738.	1.4	20
57	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. Journal of Infectious Diseases, 2015, 212, 596-607.	1.9	138
58	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 2015, 12, e1001810.	3.9	188
59	Trends of HIV-1 incidence with credible intervals in Sweden 2002â€“09 reconstructed using a dynamic model of within-patient IgG growth. International Journal of Epidemiology, 2015, 44, 998-1006.	0.9	12
60	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 1735-1744.	1.9	62
61	Population genomics of intrapatient HIV-1 evolution. ELife, 2015, 4, .	2.8	206
62	Temporal Trends in the Swedish HIV-1 Epidemic: Increase in Non-B Subtypes and Recombinant Forms over Three Decades. PLoS ONE, 2014, 9, e99390.	1.1	48
63	Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic. PLoS ONE, 2014, 9, e101738.	1.1	36
64	Timing and Order of Transmission Events Is Not Directly Reflected in a Pathogen Phylogeny. Molecular Biology and Evolution, 2014, 31, 2472-2482.	3.5	85
65	Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scandinavian Journal of Infectious Diseases, 2014, 46, 673-677.	1.5	24
66	Evaluation of Bio-Rad Geenius HIV-1 and -2 Assay as a Confirmatory Assay for Detection of HIV-1 and -2 Antibodies. Vaccine Journal, 2014, 21, 1192-1194.	3.2	13
67	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. PLoS ONE, 2014, 9, e94495.	1.1	32
68	Towards Estimation of HIV-1 Date of Infection: A Time-Continuous IgG-Model Shows That Seroconversion Does Not Occur at the Midpoint between Negative and Positive Tests. PLoS ONE, 2013, 8, e60906.	1.1	24
69	Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003â€“2010. PLoS ONE, 2012, 7, e33484.	1.1	56
70	Towards a world free from HIV and AIDS?. Journal of Internal Medicine, 2011, 270, 502-508.	2.7	1
71	Dynamics of Two Separate but Linked HIV-1 CRF01_AE Outbreaks among Injection Drug Users in Stockholm, Sweden, and Helsinki, Finland. Journal of Virology, 2011, 85, 510-518.	1.5	43
72	Multiple HIV-1 introductions into the Swedish intravenous drug user population. Infection, Genetics and Evolution, 2008, 8, 545-552.	1.0	13

#	Article	IF	Citations
73	Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. Journal of General Virology, 2007, 88, 1526-1531.	1.3	121
74	Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines. Journal of Internal Medicine, 2007, 262, 2-4.	2.7	1
75	HIV-1 Transmission Cluster with M41L â€˜Singletonâ€™ Mutation and Decreased Transmission of Resistance in Newly Diagnosed Swedish Homosexual Men. Antiviral Therapy, 2006, 11, 1031-1040.	0.6	23
76	Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. Journal of General Virology, 2005, 86, 2859-2869.	1.3	56
77	Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. Journal of General Virology, 2005, 86, 3385-3396.	1.3	69
78	Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing. Antiviral Therapy, 2004, 9, 829-848.	0.6	114
79	Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiologica Scandinavica, 2003, 47, 407-410.	0.7	44
80	A Comparison of the Antiplatelet Effect of S-Nitrosoglutathione in Whole Blood and Platelet-Rich Plasma. Thrombosis Research, 2001, 102, 161-165.	0.8	14
81	Evidence of the Existence of a New Circulating Recombinant Form of HIV Type 1 Subtype A/J in Cameroon. AIDS Research and Human Retroviruses, 2000, 16, 1313-1318.	0.5	23
82	Monoclonal Antibodies to Native HIV Type 1 Reverse Transcriptase and Their Interaction with Enzymes from Different Subtypes. AIDS Research and Human Retroviruses, 2000, 16, 1281-1294.	0.5	9
83	Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment. International Journal of STD and AIDS, 1999, 10, 514-521.	0.5	2
84	The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10752-10757.	3.3	158
85	Inhaled nitric oxide does not influence bleeding time or platelet function in healthy volunteers. European Journal of Clinical Investigation, 1999, 29, 953-959.	1.7	21
86	Neither endogenous nor inhaled nitric oxide influences the function of circulating platelets in healthy volunteers. Clinical Science, 1999, 97, 345-53.	1.8	3
87	Blockade of endogenous nitric oxide production results in moderate hypertension, reducing sympathetic activity and shortening bleeding time in healthy volunteers. Acta Anaesthesiologica Scandinavica, 1997, 41, 1104-1113.	0.7	27
88	Effective systemic blockade of endogenous nitric oxide production results in moderate hypertension, reduced sympathetic activity and shortened bleeding time in healthy volunteers. Acta Anaesthesiologica Scandinavica, 1997, 41, 159-160.	0.7	4
89	Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. Journal of Virology, 1997, 71, 4761-4770.	1.5	124
90	Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10864-10869.	3.3	239

#	Article	IF	Citations
91	Longâ€“term protection against SIVâ€“induced disease in macaques vaccinated with a live attenuated HIVâ€“2 vaccine. Nature Medicine, 1995, 1, 914-918.	15.2	71
92	Cross-Resistance between AZT, ddI and other Antiretroviral Drugs in Primary Isolates of HIV-1. Antiviral Chemistry and Chemotherapy, 1994, 5, 7-12.	0.3	13
93	Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes. Journal of Virology, 1994, 68, 5918-5924.	1.5	145
94	Human immunodeficiency virus type 1 and cytomegalovirus in saliva. Journal of Medical Virology, 1993, 39, 156-162.	2.5	48
95	Group Specific Component and Susceptibility to HIV Infection and Progression to AIDS. Scandinavian Journal of Infectious Diseases, 1988, 20, 11-14.	1.5	4
96	Site-directed ELISA with synthetic peptides representing the HIV transmembrane glycoprotein. Journal of Medical Virology, 1987, 23, 1-9.	2.5	56
97	Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. Journal of Medical Virology, 1987, 23, 67-73.	2.5	115